A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1733 views | HTML 2924 views | ?
Hayley Nehoff1, Neha N. Parayath1, Melanie J. McConnell2, Sebastien Taurin1, Khaled Greish1
1Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand
2School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand
Sebastien Taurin, e-mail: [email protected]
Keywords: glioblastoma multiforme, tyrosine kinase inhibitors, invasion, Met, SRC
Received: April 23, 2015 Accepted: October 06, 2015 Published: October 16, 2015
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor. Despite the advances in surgery, radiotherapy and chemotherapy, patient survival averages only 14.6 months. In most GBM tumors, tyrosine kinases show increased activity and/or expression and actively contribute to the development, recurrence and onset of treatment resistance; making their inhibition an appealing therapeutic strategy. We compared the cytotoxicity of 12 tyrosine kinase inhibitors in vitro. A combination of crizotinib and dasatinib emerged as the most cytotoxic across established and primary human GBM cell lines. The combination treatment induced apoptotic cell death and polyploidy. Furthermore, the combination treatment led to the altered expression and localization of several tyrosine kinase receptors such as Met and EGFR and downstream effectors as such as SRC. Furthermore, the combination treatment reduced the migration and invasion of GBM cells and prevented endothelial cell tube formation in vitro. Overall, our study demonstrated the broad specificity of a combination of crizotinib and dasatinib across multiple GBM cell lines. These findings provide insight into the development of alternative therapy for the treatment of GBM.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.